COMPANY PROFILE

Sidera Bio

Explore full profile

Advancing genetic discoveries to enhance precision medicine through large-scale data analyses

Copenhagen, DenmarkFounded 2023Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Sidera Bio

SideraBio is focused on advancing the understanding of human genetics to accelerate the discovery of genes related to disease susceptibility and protection. The company operates in the precision medicine market, utilizing comprehensive, large-scale data analyses and innovative research methodologies. By integrating multiple datasets and diverse experimental designs, SideraBio aims to uncover genetic insights that can be transformed into actionable health solutions. This approach supports the development of personalized medicine, offering tailored healthcare solutions based on individual genetic profiles. SideraBio's business model revolves around providing these genetic insights to healthcare providers and researchers, facilitating the creation of targeted therapies and interventions. The company generates revenue by offering its expertise and data-driven solutions to clients in the healthcare and pharmaceutical industries.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Copenhagen, Denmark
Employees: 6
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Biotech and Pharma, AI Drug Discovery, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Dec 2025	$109M	$436M	RA Capital Management · Forbion Capital Partners · Gilde Healthcare · Novo Holdings	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Sidera Bio website traffic

Latest recorded traffic for Sidera Bio is 1.9K monthly website visits, up 1257.1% over the last three months.

Latest monthly visits1.9K 3-month web change+1257.1%

Monthly website visitsDec 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
NANorVita Med AsPatient-derived organoid and neuron models for drug discovery and precision medicine in mitochondrial disease therapy	—	Operational
DLDante LabsGenomic and precision medicine solutions, from whole genome sequencing and interpretation to data-driven drug discovery	Hendersonville, United States	Operational
PBPrecision BioPharmaPioneering drug development with AI-driven Adaptive Translational Research for rapid discovery and regulatory success	Stockholm, United States	Operational
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
PTParadigm TherapeuticsBiopharmaceutical solutions for Epidermolysis Bullosa, offering comprehensive topical treatments for all subtypes	Mount Pleasant, United States	Operational
ETEtiomeBiostaged Medicines targeting disease progression with stage-specific therapies for improved health outcomes	Cambridge, United States	Operational
RBRadical BioHigh-resolution mass spectrometry for precise disease-specific protein structure analysis in drug discovery	Madison, United States	Operational